V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20158621 | 20134482 | 1.64 | 78 | Palliative (P) | 2019-11-27 | 2020-01-17 | ST03 TRIAL | 2 | N | SCOPE2 TRIAL | 101435620 |
| 20158965 | 20134483 | 1.69 | 53.8 | Palliative (P) | 2018-05-29 | 2018-07-16 | Bevacizumab + Irinotecan + MdG | 02 | null | CISPLATIN + PEMETREXED | 101443493 |
| 20159169 | 20134485 | 1.65 | 72.3 | 03 | 2015-03-09 | 2017-05-10 | MELPHALAN | null | N | CISPLATIN + CYCLOPHOSPHAMIDE + DOXORUBICIN | 100933100 |
| 20159217 | 20134486 | 1.69 | 82.1 | null | 2021-11-01 | 2021-11-03 | COSMIC TRIAL | 02 | N | CARBOPLATIN + PEMBROLIZUMAB + PEMETREXED | 100609557 |
| 20159362 | 20134488 | 1.76 | 88.7 | null | 2019-02-09 | 2019-03-04 | CISPLATIN + DOCETAXEL + FLUOROURACIL | 02 | null | SCOPE2 TRIAL | 101603763 |
| 20159370 | 20134489 | 1.91 | 81.5 | null | 2019-12-15 | 2020-10-30 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 02 | null | CAPECITABINE + STREPTOZOCIN | 101429125 |
| 20159558 | 20134490 | 1.71 | 56.8 | Palliative (P) | 2019-10-06 | 2019-10-13 | CISPLATIN + TEYSUNO | 2 | null | CARBOPLATIN + PEMETREXED | 100141661 |
| 20159617 | 20134491 | 1.56 | 81.6 | Neo-adjuvant (N) | 2011-03-22 | 2021-07-03 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 99 | N | CAPECITABINE + OXALIPLATIN + TRASTUZUMAB | 100459460 |
| 20159702 | 20134492 | 1.77 | 105 | Palliative (P) | 2018-05-22 | 2018-05-22 | Bevacizumab + Irinotecan + MdG | 02 | null | CETUXIMAB + FLUOROURACIL | 100838496 |
| 20159997 | 20134493 | 1.86 | 121 | null | 2017-11-02 | 2017-11-04 | FCiSt | 02 | N | NAB-PACLITAXEL | 100350157 |
| 20160104 | 20134495 | 1.56 | 9.2 | Palliative (P) | null | 2019-05-28 | Carboplatin+Fluorouracil 4 or 5 day | 02 | null | AFATINIB | 100803207 |
| 20160123 | 20134496 | 1.79 | 24.4 | null | 2019-02-17 | 2019-02-26 | Carboplatin + Pemetrexed | 02 | null | DOCETAXEL + NINTEDANIB | 100490191 |
| 20160182 | 20134497 | 1.57 | 78.4 | Palliative (P) | null | 2019-12-23 | PLATO Trials | null | N | FLUOROURACIL + RT | 101181204 |
| 20160321 | 20134498 | 1.79 | 65 | Curative (C) | 2019-05-31 | 2019-06-03 | Ipilimumab | 02 | N | CISPLATIN + FLUOROURACIL + TRASTUZUMAB | 101866424 |
| 20160619 | 20134500 | 1.72 | 70 | Palliative (P) | 2018-04-15 | 2018-04-21 | Gemcitabine + RT pancreas | N | N | STAR TRIAL | 100264511 |
| 20160629 | 20134501 | null | 83.6 | null | null | 2020-07-27 | Bortezomib + Daratumumab | null | N | BEVACIZUMAB + FLUOROURACIL + OXALIPLATIN | 101802734 |
| 20160672 | 20134502 | 0.7 | 53.2 | null | 2021-05-09 | 2021-05-10 | ARISTOTLE TRIAL | 02 | null | CISPLATIN + PEMETREXED | 100029367 |
| 20160756 | 20134503 | 1.78 | 116 | Palliative (P) | 2022-02-09 | 2022-02-16 | BCG Intravesical | 02 | Y | BEAM | 101856025 |
| 20161010 | 20134504 | 1.49 | 68.6 | null | 2018-11-28 | 2018-12-10 | DABRAFENIB + TRAMETINIB | 02 | null | GEMCITABINE + PACLITAXEL | 100243890 |
| 20161127 | 20134505 | 1.69 | 59.8 | Palliative (P) | 2018-02-28 | 2018-06-11 | Palbociclib | 02 | N | BRENTUXIMAB | 101731971 |
| 20161356 | 20134507 | 1.41 | 83 | null | 2017-04-11 | 2017-04-30 | PRIMUS 002 TRIAL | 02 | null | TRABECTEDIN | 100087950 |
| 20161377 | 20134508 | 1.71 | 9.2 | null | 2020-01-03 | 2020-01-23 | EOF | 02 | N | CARBOPLATIN + VINORELBINE | 101086605 |
| 20161556 | 20134509 | 1.85 | 85.1 | Curative (C) | 2018-01-08 | 2018-01-22 | Fluorouracil + Folinic + RT Bossett | 02 | null | CISPLATIN + PEMETREXED | 101182578 |
| 20161884 | 20134510 | 1.8 | 68.2 | Palliative (P) | 2019-11-02 | 2019-11-10 | null | 02 | N | TEYSUNO | 100215132 |
| 20162242 | 20134511 | 1.66 | 72.7 | null | 2022-02-10 | 2022-02-10 | IVE | null | N | IRINOTECAN + PANITUMUMAB | 101588994 |
| 20163011 | 20134514 | 1.8 | 10.2 | Disease modification (D) | null | 2019-06-01 | CAV | 02 | N | BEVACIZUMAB + CAPECITABINE + OXALIPLATIN | 100465565 |
| 20163720 | 20134516 | 1.52 | null | Curative (C) | 2017-08-19 | 2018-06-04 | Cisplatin +FU +Trastuzumab - Load | N | N | IPILIMUMAB + NIVOLUMAB | 100483954 |
| 20163753 | 20134517 | 1.48 | 61.2 | Adjuvant (A) | 2019-10-25 | 2019-10-25 | CAP + RT | 02 | null | TRABECTEDIN | 100060253 |
| 20164336 | 20134518 | 1.75 | 73.2 | null | 2018-02-05 | 2018-02-14 | BORTEZOMIB + THALIDOMIDE | 02 | N | CAPE + OXALIPLATIN + TRASTUZUMAB | 101712263 |
| 20164782 | 20134519 | 1.6 | 94.8 | Palliative (P) | 2019-10-31 | 2019-11-11 | CAPE + OXALIPLATIN + TRASTUZUMAB | 02 | N | BACILLUS CALMETTE-GUERIN | 100187380 |
| 20165185 | 20134520 | 0 | 0 | null | 2017-04-01 | 2017-04-01 | Cetuximab + FLUOROURACIL | 02 | null | ATEZOLIZUMAB | 101802594 |
| 20166245 | 20134522 | 1.81 | 0 | Palliative (P) | null | 2017-01-01 | INTERAACT trial | 02 | null | NILOTINIB | 100000864 |
| 20166383 | 20134523 | 1.65 | 59.6 | Palliative (P) | null | 2018-09-25 | Hepatoblastoma Relapse VI | null | N | PEMETREXED | 101279804 |
| 20166559 | 20134524 | 1.82 | 53 | 03 | 2017-09-23 | 2018-09-07 | CAPE + OXALIPLATIN + TRASTUZUMAB | N | N | CISPLATIN + VINORELBINE | 100036528 |
| 20166977 | 20134525 | 1.8 | 92 | Palliative (P) | 2020-02-25 | 2020-03-07 | Capital Trial | 02 | N | LETROZOLE + PALBOCICLIB | 101172167 |
| 20167074 | 20134527 | 1.51 | 62.5 | Palliative (P) | 2021-07-03 | 2021-07-03 | OXALIPLATIN + MDG + PANITUMUMAB | 02 | N | AZACITIDINE | 100949572 |
| 20167124 | 20134528 | 1.69 | 72.1 | 03 | 2019-10-29 | 2019-11-01 | Bevacizumab + Cape + Oxali 21day | 02 | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | 101092406 |
| 20167281 | 20134529 | 1.89 | 53.2 | Palliative (P) | 2016-11-26 | 2016-12-05 | FCarboSt | 02 | N | BACILLUS CALMETTE-GUERIN | 101265092 |
| 20167528 | 20134530 | 1.75 | 13 | Not known (9) | 2017-11-07 | 2017-11-09 | Bendamustine+Rituximab(Sub Courses) | 02 | N | EOF | 101513744 |
| 20167598 | 20134531 | 1.8 | 52.6 | Palliative (P) | 2020-10-28 | 2020-11-11 | FCiSt | 02 | N | GEFITINIB | 100419704 |
| 20167640 | 20134532 | 1.69 | 101.8 | Palliative (P) | 2019-02-28 | 2019-03-15 | FOCUS4 TRIAL | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVA | 100378508 |
| 20167655 | 20134533 | 1.8 | 98 | Palliative (P) | 2019-07-13 | 2019-07-21 | Cisplatin + Docetaxel | 02 | N | FOCUS4 TRIAL | 100695041 |
| 20167684 | 20134534 | 1.6 | 66.5 | null | 2017-08-07 | 2017-08-18 | DARATUMUMAB | 02 | null | CISPLATIN + FLUOROURACIL + RT | 100773168 |
| 20167749 | 20134535 | 1.68 | 110 | Palliative (P) | 2016-11-10 | 2016-11-24 | Gemcitabine+Paclitaxel (Neo-tAnGo) | 2 | N | CABAZITAXEL | 100769087 |
| 20167950 | 20134536 | 1.79 | null | null | 2021-09-01 | 2021-09-07 | CHOP R - 21 days | 02 | null | CAPECITABINE + MITOMYCIN + RT | 100942228 |
| 20168615 | 20134537 | 1.83 | 66.2 | null | 2017-05-14 | 2017-05-26 | DARATUMUMAB | 02 | null | COSMIC TRIAL | 101279647 |
| 20169007 | 20134538 | 0 | 104.7 | Palliative (P) | 2019-01-18 | 2019-01-18 | IBRUTINIB | 02 | N | SCOPE2 TRIAL | 100987130 |
| 20169092 | 20134540 | 1.69 | 101.3 | Curative (C) | 2015-09-14 | 2018-02-19 | Cisplatin + Docetaxel | 99 | N | CISPLATIN + FU + TRASTUZUMAB | 100274021 |
| 20169180 | 20134542 | 1.8 | 52.5 | Palliative (P) | 2017-06-19 | 2017-12-26 | null | Y | null | CARBOPLATIN + PEMETREXED | 100813839 |
| 20169414 | 20134543 | 1.61 | 47.2 | Palliative (P) | 2019-02-26 | 2019-03-15 | Paclitaxel albumin (Abraxane) 21day | 02 | Y | FOXFIRE TRIAL | 100394032 |